Latest Capital Raising News

Lefroy Exploration Limited reported a modest net cash decrease in the December quarter, ending with $3.24 million in cash reserves and nearly four quarters of funding available. The company continues to invest heavily in exploration activities despite operating cash outflows.

Gratifii reports a remarkable 110% increase in 2Q FY25 cash receipts, driven by strategic acquisitions and strong client engagement, setting the stage for sustained growth and profitability in the coming quarters.

Novatti Group Limited reports a robust December quarter with a 30% year-on-year revenue increase and a significant reduction in expenses, positioning the fintech on track for positive operating cashflow by mid-2025.

Dubber Corporation Limited reports steady revenue growth and cost reductions in Q2 FY25, alongside a refreshed board and strategic initiatives aimed at achieving operating cashflow breakeven by year-end.

Vulcan Energy Resources reported a robust cash position of €97 million at the end of 2024 despite significant cash outflows driven by exploration and development activities. The company’s strong liquidity is supported by unused financing facilities, positioning it well for upcoming operational demands.

Vulcan Energy has marked a pivotal quarter with major capital raises, strategic partnerships, and the commencement of Europe’s first fully integrated battery-quality lithium hydroxide production.

Torque Metals delivers standout drilling results at its Paris Gold Project, confirming high-grade gold zones beyond existing resources, while bolstering its portfolio with new gold and lithium tenements and a successful $1M share placement.

Control Bionics has delivered its strongest US sales quarter in years, nearing US$1 million in revenue, while broadening its market footprint with new commercial agreements and cost optimizations.

Dragon Mountain Gold Limited reports promising drilling results at its Avalon Project and prepares for further exploration at Cawse, supported by a successful $670,000 capital raise and strategic board appointment.

Percheron Therapeutics has terminated its phase IIb avicursen trial for Duchenne muscular dystrophy after failing to meet efficacy endpoints, while securing $14.85 million in fresh capital to explore new therapeutic opportunities.

Advance Metals Limited has significantly expanded its portfolio with binding agreements to acquire high-grade silver and gold projects in Mexico and Australia, setting the stage for an active 2025 exploration campaign.

Elixir Energy wraps up Daydream-2 well operations and prepares for next appraisal in a strengthening gas market, while progressing farmout talks for Australian and Mongolian assets.